Variability in grading of ductal carcinoma in situ among an international group of pathologists.
Biomarkers, Tumor
/ analysis
Biopsy
Breast Neoplasms
/ chemistry
Carcinoma, Intraductal, Noninfiltrating
/ chemistry
Europe
Female
Humans
Immunohistochemistry
Neoplasm Grading
Observer Variation
Pathologists
Predictive Value of Tests
Receptor, ErbB-2
/ analysis
Receptors, Estrogen
/ analysis
Reproducibility of Results
Retrospective Studies
United States
ductal carcinoma in situ
grade
interobserver variability
pathology
Journal
The journal of pathology. Clinical research
ISSN: 2056-4538
Titre abrégé: J Pathol Clin Res
Pays: England
ID NLM: 101658534
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
revised:
11
12
2020
received:
25
09
2020
accepted:
08
01
2021
pubmed:
24
2
2021
medline:
27
1
2022
entrez:
23
2
2021
Statut:
ppublish
Résumé
The prognostic value of cytonuclear grade in ductal carcinoma in situ (DCIS) is debated, partly due to high interobserver variability and the use of multiple guidelines. The aim of this study was to evaluate interobserver agreement in grading DCIS between Dutch, British, and American pathologists. Haematoxylin and eosin-stained slides of 425 women with primary DCIS were independently reviewed by nine breast pathologists based in the Netherlands, the UK, and the USA. Chance-corrected kappa (κ
Identifiants
pubmed: 33620141
doi: 10.1002/cjp2.201
pmc: PMC8073001
doi:
Substances chimiques
Biomarkers, Tumor
0
Receptors, Estrogen
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
233-242Subventions
Organisme : Cancer Research UK
ID : C38317/A24043
Pays : United Kingdom
Informations de copyright
© 2021 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland & John Wiley & Sons, Ltd.
Références
Breast Cancer Res Treat. 2013 Jun;139(3):639-47
pubmed: 23774990
Eur J Cancer. 2018 Sep;101:210-219
pubmed: 30092498
Eur J Cancer. 2015 Nov;51(16):2296-303
pubmed: 26296293
Mod Pathol. 2020 Oct;33(10):1961-1967
pubmed: 32404951
Clin Cancer Res. 2018 Aug 1;24(15):3593-3601
pubmed: 29685879
CA Cancer J Clin. 2015 Nov-Dec;65(6):481-95
pubmed: 26431342
J Clin Oncol. 2001 Apr 15;19(8):2263-71
pubmed: 11304780
BMJ Open. 2019 Mar 12;9(3):e026797
pubmed: 30862637
Eur J Cancer. 2017 Jul;80:39-47
pubmed: 28535496
JAMA. 2015 Mar 17;313(11):1122-32
pubmed: 25781441
Br J Cancer. 2011 Jan 4;104(1):120-7
pubmed: 21139586
J Clin Pathol. 2020 Dec;73(12):793-799
pubmed: 32276993
Br J Cancer. 2008 Jan 15;98(1):137-42
pubmed: 18043578
Am J Surg Pathol. 2019 Nov;43(11):1574-1582
pubmed: 31206365
J Clin Pathol. 2017 Jan;70(1):51-57
pubmed: 27406051
Arch Pathol Lab Med. 2013 Apr;137(4):462-6
pubmed: 23544935
Arch Pathol Lab Med. 2009 Jan;133(1):15-25
pubmed: 19123730
Histopathology. 2018 Dec;73(6):923-932
pubmed: 30168167
Stat Med. 2015 Oct 15;34(23):3116-32
pubmed: 26095449
Br J Cancer. 2019 Aug;121(4):285-292
pubmed: 31285590
Br J Cancer. 2010 Jun 29;103(1):94-100
pubmed: 20517310
Am J Clin Pathol. 2020 Feb 8;153(3):360-367
pubmed: 31769792
Breast Cancer Res Treat. 2016 Oct;159(3):553-63
pubmed: 27624164
Stat Methods Med Res. 2018 Mar;27(3):812-831
pubmed: 27184590
Pathol Res Pract. 2010 Oct 15;206(10):705-11
pubmed: 20663616
Breast Cancer Res. 2008;10(4):R67
pubmed: 18681955
Eur J Cancer. 2015 Aug;51(12):1497-510
pubmed: 26025767
Ann Epidemiol. 2017 Oct;27(10):677-685.e4
pubmed: 29029991
Eur J Cancer. 2000 Sep;36(14):1769-72
pubmed: 10974624
Cancer. 1997 Nov 1;80(9):1798-802
pubmed: 9351550
BMJ. 2016 Jun 22;353:i3069
pubmed: 27334105
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Breast Cancer Res Treat. 2020 Oct;183(3):759-770
pubmed: 32734520
Mod Pathol. 1998 Feb;11(2):155-68
pubmed: 9504686
Diagn Pathol. 2015 Jul 10;10:93
pubmed: 26159429